{"meta":{"query_hash":"31c98ffb0e4d","filters":{"venue":"Liver Cancer"},"cohort_total":19,"direct_labels_cover":0,"predictions_cover":19,"exported":19,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/31c98ffb0e4d","api":"https://metacan.xera.ac/api/v1/cohort?venue=Liver+Cancer"},"results":[{"id":"W2106822989","doi":"10.1007/978-1-4020-9804-8_7","title":"Intraoperative Magnetic Resonance Imaging for Radiofrequency Ablation of Hepatic Tumors","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Debulking; Radiofrequency ablation; Magnetic resonance imaging; Radiology; Ablation; Interventional magnetic resonance imaging; Cancer","score_opus":0.036948709249089606,"score_gpt":0.2508398812122156,"score_spread":0.21389117196312601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106822989","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012886647,0.67219645,0.00040903146,0.0010886914,0.00043742862,0.0061625866,0.0006327712,0.0001375132,0.3060489],"genre_scores_gemma":[0.5292595,0.019762576,0.004963358,0.00092042465,0.0010734504,0.00049655634,0.0005010181,0.00019914341,0.44282395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877167,0.000014628367,0.0003800919,0.00036700623,0.00025309325,0.000213527],"domain_scores_gemma":[0.99917436,0.00005885176,0.00018804069,0.00025539516,0.00023702905,0.000086336106],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008119152,0.00031290908,0.0005871811,0.00014209519,0.000051138468,0.000011673628,0.000079540776,0.00014080355,0.0010461954],"category_scores_gemma":[0.000014085076,0.00028292518,0.00024056136,0.0000459177,0.00009724283,0.000111194706,0.0000125297065,0.00017030636,0.000017320841],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035483303,0.00006175697,0.040556792,0.00060021284,0.00012710312,0.00023993092,0.0009424043,0.0000011545487,0.000551675,0.011965265,0.0012089484,0.94338995],"study_design_scores_gemma":[0.015554401,0.0070948424,0.06062334,0.018986976,0.009765412,0.00023421568,0.00008182975,0.022587888,0.021218952,0.028229337,0.81216747,0.0034553248],"about_ca_topic_score_codex":0.00017195249,"about_ca_topic_score_gemma":0.000030718766,"teacher_disagreement_score":0.9399346,"about_ca_system_score_codex":0.0002977877,"about_ca_system_score_gemma":0.00025022958,"threshold_uncertainty_score":0.9999623},"labels":[],"label_agreement":null},{"id":"W2131550821","doi":"10.1007/978-1-4020-9804-8_5","title":"Selection of Patients for Resection of Hepatic Colorectal Metastases: 18F-Fluorodeoxyglucose/Positron Emission Tomography","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Positron emission tomography; Colorectal cancer; Radiology; Fluorodeoxyglucose; Stage (stratigraphy); Cancer; Internal medicine","score_opus":0.030148028319682434,"score_gpt":0.2518629784872493,"score_spread":0.22171495016756687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131550821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9485987,0.012233096,0.00014222387,0.000052299634,0.00055941613,0.005723504,0.0012444113,0.000097943164,0.031348422],"genre_scores_gemma":[0.9747331,0.0017281132,0.00078872644,0.000036177906,0.00020359509,0.00016968326,0.0010288238,0.00007254903,0.021239229],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985079,0.000031882773,0.00048295571,0.00037471938,0.00039914067,0.00020337902],"domain_scores_gemma":[0.99865943,0.0000639261,0.00046950456,0.00018474381,0.0005173045,0.00010508362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010985913,0.0003233602,0.00071638724,0.000365396,0.000061190825,0.0000058434566,0.000063663865,0.00027035965,0.00034828478],"category_scores_gemma":[0.000016371127,0.00028585194,0.00054817495,0.0001137261,0.00006132218,0.00007000852,0.000018912353,0.00018132883,0.0000025091917],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017874705,0.0017350494,0.7048594,0.0060368604,0.004904547,0.00002617157,0.00073442474,0.000003683933,0.026700722,0.00082040596,0.012173995,0.22413006],"study_design_scores_gemma":[0.011226664,0.02879383,0.054175384,0.004892489,0.014531642,0.000016636875,0.000018801955,0.0013722202,0.81478703,0.0012753159,0.06769733,0.001212652],"about_ca_topic_score_codex":0.00023001934,"about_ca_topic_score_gemma":0.00007914462,"teacher_disagreement_score":0.7880863,"about_ca_system_score_codex":0.00023663565,"about_ca_system_score_gemma":0.00014951108,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W2559460526","doi":"10.1159/000449346","title":"Hepatocellular Carcinoma: The Role of Interventional Oncology","year":2016,"lang":"en","type":"review","venue":"Liver Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Liver transplantation; Incidence (geometry); Surgical resection; Internal medicine; Oncology; Transplantation; General surgery","score_opus":0.047641164081696316,"score_gpt":0.3697047981926722,"score_spread":0.3220636341109759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559460526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019649394,0.9974464,0.0004512033,0.000017685907,0.00027768634,0.0002941189,0.00016435112,0.000002852891,0.0011491643],"genre_scores_gemma":[0.00045013186,0.9963307,0.0002636623,0.000037822254,0.00053398294,0.00012992181,0.00007945372,0.000027470482,0.0021468885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988663,0.00034727392,0.00031738076,0.00026151683,0.00007431503,0.00013316657],"domain_scores_gemma":[0.9991361,0.000044139106,0.00036554987,0.00033173893,0.00009386268,0.000028639508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021943181,0.00017438839,0.0004560569,0.000036338937,0.000031564487,0.0000046980936,0.00032426752,0.00029570266,0.00062434433],"category_scores_gemma":[0.000032891494,0.00010373862,0.00043343424,0.000062738065,0.00011683822,0.0000015889906,0.00017874887,0.00012585272,0.000020656276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012198435,0.000035798435,0.00007390619,0.0010116857,0.000202743,0.0000013960714,0.000014089887,9.835491e-8,0.008889583,0.00031892306,0.0021421923,0.98729736],"study_design_scores_gemma":[0.0000908515,0.00006915673,0.000007300598,0.00085615355,0.00014743407,0.000012017345,0.0000051728234,0.0000011637128,0.009349097,0.000042512125,0.9892987,0.00012045284],"about_ca_topic_score_codex":0.000090173795,"about_ca_topic_score_gemma":0.000012726479,"teacher_disagreement_score":0.98717695,"about_ca_system_score_codex":0.00008511147,"about_ca_system_score_gemma":0.00040764824,"threshold_uncertainty_score":0.68361324},"labels":[],"label_agreement":null},{"id":"W3139664658","doi":"10.36255/exonpublications.livercancer.2021.ch4","title":"Gross Dissection of Liver for Hepatocellular Carcinoma Using AJCC Cancer Staging Manual 8th Edition: Anatomical and Practical Considerations","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta; University of Alberta Hospital","funders":"","keywords":"Dissection (medical); Hepatocellular carcinoma; Medicine; Liver cancer; Cancer; General surgery; Terminology; Resection; Pathology; Radiology; Surgery; Internal medicine","score_opus":0.07437325643932621,"score_gpt":0.348629559974269,"score_spread":0.2742563035349428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139664658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89663476,0.08131549,0.0011717,0.0018365915,0.0024533633,0.0037303274,0.005159743,0.00011571574,0.007582309],"genre_scores_gemma":[0.9739145,0.003107921,0.0009983642,0.00035005904,0.002185237,0.00018833566,0.00012640136,0.00009324333,0.019035932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985079,0.000022787144,0.00036688146,0.0005181197,0.00033639316,0.0002478846],"domain_scores_gemma":[0.9986308,0.00021612318,0.00014697372,0.00021301214,0.00061242573,0.00018063997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006724433,0.00030959633,0.0006227596,0.00012104171,0.00021814332,0.00003162289,0.000016483416,0.0002227859,0.0015634452],"category_scores_gemma":[0.00005479429,0.00032082273,0.00020789268,0.000038379712,0.0003108382,0.00014659214,0.00010075486,0.00031898398,0.0000021498618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01166375,0.0021822588,0.41130808,0.050440643,0.024285864,0.03203464,0.016058171,0.00006455136,0.025516693,0.262928,0.11873548,0.044781875],"study_design_scores_gemma":[0.03705126,0.003995644,0.26943034,0.032114707,0.08303236,0.010825111,0.0067251734,0.22917864,0.039116744,0.021952862,0.25387827,0.012698893],"about_ca_topic_score_codex":0.0006163162,"about_ca_topic_score_gemma":0.00073006,"teacher_disagreement_score":0.24097514,"about_ca_system_score_codex":0.0003877948,"about_ca_system_score_gemma":0.0008397869,"threshold_uncertainty_score":0.99992436},"labels":[],"label_agreement":null},{"id":"W3173725877","doi":"10.1159/000513486","title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Bevacizumab; Medicine; Internal medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Gastroenterology; Progression-free survival; Population; Phases of clinical research; Oncology; Clinical endpoint; Randomized controlled trial; Clinical trial; Confidence interval; Cancer; Chemotherapy; Nivolumab; Immunotherapy","score_opus":0.10695670752842361,"score_gpt":0.34804486855848377,"score_spread":0.24108816103006014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173725877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335576,0.008258672,0.000051480853,0.00065380015,0.0002613661,0.005240662,0.00003362652,0.000043563396,0.0021010742],"genre_scores_gemma":[0.99598765,0.00030990885,0.00017767909,0.00020212446,0.00021806949,0.0016869609,0.00028978233,0.00006218074,0.0010656381],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99683803,0.00070009177,0.00050318486,0.00071649684,0.000721398,0.00052080926],"domain_scores_gemma":[0.9983559,0.00030280495,0.00016657397,0.00077466946,0.00024112267,0.00015892224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006860938,0.0004438286,0.0010947756,0.00014970262,0.00023822117,0.00020343758,0.00037143083,0.00012413536,0.0006463949],"category_scores_gemma":[0.00009243822,0.0002714293,0.0001512669,0.0010983687,0.00010918567,0.00032175536,0.00017607262,0.00037347086,0.000037554953],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1838967,0.003451316,0.7974388,0.00010528552,0.00061558106,0.006540092,0.005354702,0.0000141650125,0.000207348,0.00010690668,0.00014720885,0.0021218918],"study_design_scores_gemma":[0.9267568,0.002145923,0.033888854,0.00013654496,0.0019472743,0.00015367287,0.0017759036,0.030738577,0.0013368306,0.000053623146,0.0005451157,0.0005208683],"about_ca_topic_score_codex":0.012336505,"about_ca_topic_score_gemma":0.0058082636,"teacher_disagreement_score":0.7635499,"about_ca_system_score_codex":0.0004828597,"about_ca_system_score_gemma":0.0007334634,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W3185994964","doi":"10.1159/000516490","title":"Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eisai","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Liver function; Adverse effect; Oncology; Overall survival; Post-hoc analysis; Gastroenterology","score_opus":0.05933619209472887,"score_gpt":0.2809289060137234,"score_spread":0.22159271391899452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185994964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947729,0.0037731426,0.000021454905,0.00012868171,0.000056340876,0.0010964376,0.000032050833,0.000011735477,0.000107253705],"genre_scores_gemma":[0.9990334,0.00015557618,0.00004648205,0.00022349133,0.000038605864,0.00017422083,0.000085769214,0.000018983956,0.00022346426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986406,0.0002119358,0.00023013083,0.0003129908,0.00040330834,0.00020101416],"domain_scores_gemma":[0.9992771,0.00008309575,0.000075045646,0.0003090469,0.0001887999,0.00006689504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019995822,0.00017638261,0.00034455126,0.00008761208,0.000060338134,0.000017571227,0.000056757413,0.00005042249,0.0003218474],"category_scores_gemma":[0.0000200733,0.00010699832,0.00005573958,0.00034091377,0.00003834174,0.00008599725,0.000034660105,0.00014098764,0.0000028768382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094435096,0.0031934802,0.9907148,0.00009654256,0.00019242348,0.00057841017,0.0017522902,9.872749e-7,0.00023528826,0.000008996399,0.000063021136,0.0022193925],"study_design_scores_gemma":[0.01200914,0.0025280374,0.98047423,0.000052429856,0.00067070447,0.0000055020264,0.0007008342,0.0011144123,0.0019132287,0.0000044634744,0.00040223415,0.000124777],"about_ca_topic_score_codex":0.0023541132,"about_ca_topic_score_gemma":0.0012484939,"teacher_disagreement_score":0.011064789,"about_ca_system_score_codex":0.00008595066,"about_ca_system_score_gemma":0.000112515445,"threshold_uncertainty_score":0.4363265},"labels":[],"label_agreement":null},{"id":"W4249856389","doi":"10.36255/exonpublications.livercancer.2021.pr","title":"Preface","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Stollery Children's Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Etiology; Fatty liver; Cancer; Liver cancer; Disease; Pathology; Internal medicine","score_opus":0.09531691578801603,"score_gpt":0.261330717019093,"score_spread":0.16601380123107695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249856389","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016905761,0.0821857,0.0000061620644,0.0005195708,0.00033842036,0.0004732202,0.00008380038,0.00007266873,0.9146299],"genre_scores_gemma":[0.016902747,0.0108187515,0.00019501187,0.000594641,0.00065740856,0.0000550763,0.00020045883,0.00007393091,0.97050196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906415,0.00000685699,0.00015262802,0.00035778678,0.00024642854,0.00017213456],"domain_scores_gemma":[0.9993424,0.000017918454,0.00006812417,0.0003321543,0.00010465882,0.00013475666],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000025626749,0.0002608899,0.0004158666,0.000057445486,0.00003519056,0.000015140488,0.000051344643,0.00029244553,0.022510884],"category_scores_gemma":[0.0000031199168,0.0002298236,0.0002830045,0.000020368705,0.000041490024,0.000025022502,0.000048162965,0.0002661342,0.0005478998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006406206,0.00035435002,0.18012777,0.0035697122,0.008646307,0.023979072,0.0015046637,0.0000010061669,0.00089749636,0.071105726,0.24511378,0.4640595],"study_design_scores_gemma":[0.00052767346,0.000093759074,0.0007230653,0.0006954758,0.0010944323,0.0000390198,0.0000031128714,0.000027926422,0.0010252221,0.00012095492,0.99540454,0.00024480748],"about_ca_topic_score_codex":0.000090974354,"about_ca_topic_score_gemma":0.000044426662,"teacher_disagreement_score":0.7502908,"about_ca_system_score_codex":0.00018382525,"about_ca_system_score_gemma":0.00027338328,"threshold_uncertainty_score":0.97838265},"labels":[],"label_agreement":null},{"id":"W4303470795","doi":"10.1159/000526899","title":"PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft; Government of Canada; Wilhelm Sander-Stiftung","keywords":"Blockade; CD8; Cytotoxic T cell; Medicine; Cancer research; Priming (agriculture); Tumor-infiltrating lymphocytes; Tumor microenvironment; Immunology; Nivolumab; Immunotherapy; Immune system; Biology; Internal medicine; Receptor","score_opus":0.02389854169721906,"score_gpt":0.3067304720411475,"score_spread":0.28283193034392845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303470795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97759265,0.01976631,0.000001276046,0.0010533974,0.00032693686,0.00064130174,0.00008545373,0.00001920315,0.0005134509],"genre_scores_gemma":[0.99462897,0.0019633,0.00012428645,0.0013209017,0.0001122347,0.0003198311,0.00001232761,0.000027891187,0.0014902388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824756,0.00008691143,0.0004924155,0.0004633188,0.00040206293,0.00030774917],"domain_scores_gemma":[0.9994091,0.000040728835,0.0001349734,0.00026007902,0.000036884903,0.00011823051],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029757744,0.0001934678,0.00036895732,0.0002590363,0.0000699347,0.000008135866,0.00011787189,0.00005824786,0.0015233268],"category_scores_gemma":[0.000018702614,0.00017894252,0.00006976684,0.00048582556,0.00007638489,0.000076770135,0.0001653087,0.00026261315,0.0000023381012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017336143,0.00027581313,0.016999172,0.00012263574,0.000037638147,0.00021827771,0.010174834,0.00017286248,0.9287466,0.0000036011716,0.0051039453,0.02080851],"study_design_scores_gemma":[0.011076553,0.0012110795,0.15672684,0.0012786093,0.00004559633,0.00005065475,0.0024092149,0.0006341613,0.78470856,0.000004003918,0.041425515,0.00042920647],"about_ca_topic_score_codex":0.017745309,"about_ca_topic_score_gemma":0.0012350244,"teacher_disagreement_score":0.14403799,"about_ca_system_score_codex":0.0010081918,"about_ca_system_score_gemma":0.0002957127,"threshold_uncertainty_score":0.9993894},"labels":[],"label_agreement":null},{"id":"W4303470808","doi":"10.1159/000527403","title":"Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; University of Pittsburgh","keywords":"Regorafenib; Cabozantinib; Discontinuation; Medicine; Hepatocellular carcinoma; Sorafenib; Hazard ratio; Propensity score matching; Adverse effect; Internal medicine; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer","score_opus":0.11114778983446884,"score_gpt":0.32787936060806316,"score_spread":0.21673157077359434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303470808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98397064,0.011931953,0.000032836277,0.00018836807,0.00035097622,0.0026144476,0.0005194049,0.000081934726,0.0003094541],"genre_scores_gemma":[0.9959449,0.00033276755,0.0008442063,0.00006666062,0.00014771089,0.000903168,0.00076213444,0.00006881211,0.00092962687],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980012,0.00014560332,0.00049344904,0.00062040664,0.00032947477,0.0004098244],"domain_scores_gemma":[0.9987333,0.00019826861,0.00027041195,0.00043305082,0.000114328875,0.00025065188],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016494861,0.00036268283,0.0009258218,0.00017320778,0.00031716755,0.000015510726,0.00011926269,0.00010054481,0.0009387053],"category_scores_gemma":[0.00001836228,0.00033466084,0.00021203338,0.00030100704,0.00008253572,0.00010801068,0.000081160346,0.00019240427,0.000003282445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042111088,0.0025118352,0.85993016,0.00047397052,0.0011759173,0.00029667327,0.011565394,0.00013223824,0.0145708155,0.00019342867,0.00026048528,0.066778],"study_design_scores_gemma":[0.20072787,0.06328855,0.22913338,0.0003549017,0.007851165,0.0001672224,0.0076387958,0.060171146,0.30686072,0.00009703803,0.1214314,0.0022778034],"about_ca_topic_score_codex":0.0012713899,"about_ca_topic_score_gemma":0.00036335396,"teacher_disagreement_score":0.6307968,"about_ca_system_score_codex":0.000387883,"about_ca_system_score_gemma":0.0002974969,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W4310183164","doi":"10.1159/000528272","title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Sorafenib; Bevacizumab; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Hazard ratio; Oncology; Liver cancer; Cancer; Phases of clinical research; Gastroenterology; Confidence interval; Chemotherapy; Nivolumab; Immunotherapy","score_opus":0.06051174997819984,"score_gpt":0.2949862541609207,"score_spread":0.2344745041827209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310183164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921583,0.0042200782,0.0000038693775,0.00002589839,0.00015844815,0.0026877937,0.0006410755,0.00002082545,0.00008374594],"genre_scores_gemma":[0.9985758,0.00030341378,0.000016736385,0.000046804525,0.000033367356,0.0005048211,0.00016573259,0.000052386516,0.00030091897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967691,0.0005260417,0.0006911019,0.00068733236,0.00090258115,0.00042387247],"domain_scores_gemma":[0.9982269,0.00014257741,0.0004171583,0.00079775235,0.00022538585,0.00019022697],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038259212,0.00036539973,0.0010743199,0.00044741924,0.00024439604,0.000013262106,0.00028563107,0.000082597806,0.002347971],"category_scores_gemma":[0.000016373568,0.00027562396,0.00022546979,0.0017100924,0.00019694984,0.00017927143,0.00031138587,0.00038409934,0.0000012767576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034745466,0.00315811,0.9471153,0.00011907656,0.0023560468,0.00014223397,0.010279471,0.0003095561,0.00009696151,0.0000061556652,0.00002100883,0.0016506319],"study_design_scores_gemma":[0.08565446,0.0053471117,0.88717335,0.00006406672,0.0063539958,5.242619e-7,0.0029831105,0.010825355,0.0010666286,7.0397215e-7,0.00019132294,0.00033937328],"about_ca_topic_score_codex":0.011984725,"about_ca_topic_score_gemma":0.0045006294,"teacher_disagreement_score":0.059941936,"about_ca_system_score_codex":0.00077850407,"about_ca_system_score_gemma":0.0007180907,"threshold_uncertainty_score":0.9999696},"labels":[],"label_agreement":null},{"id":"W4320717208","doi":"10.1159/000529636","title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Chugai Pharmaceutical; Sirtex Medical; Ipsen; Servier; Ono Pharmaceutical; Eisai; Sanofi; Bayer HealthCare; Incyte; EA Pharma Co., Ltd.; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hepatocellular carcinoma; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Physics","score_opus":0.09416067897063918,"score_gpt":0.32119857496285903,"score_spread":0.22703789599221985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320717208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813149,0.010232599,0.000060418934,0.0012362114,0.001576179,0.0044477154,0.00061548146,0.00022260429,0.00029389642],"genre_scores_gemma":[0.98209095,0.0016057167,0.000090830086,0.0012426155,0.0019561925,0.0024950893,0.001045225,0.0001148358,0.009358548],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997686,0.000102707985,0.00044000227,0.0007049253,0.00043342626,0.00063292135],"domain_scores_gemma":[0.9983451,0.00037892794,0.00016155741,0.0007099747,0.00016738888,0.00023707443],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021988673,0.0004422525,0.00064726954,0.00010975002,0.0002792226,0.000059821767,0.00026528188,0.00021585985,0.0033968969],"category_scores_gemma":[0.00005471604,0.00030334137,0.0006295028,0.00040276474,0.00010128221,0.00015215385,0.00006404699,0.00026054136,0.000285836],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32541648,0.0013977179,0.41492033,0.00023144553,0.0021152683,0.0015007465,0.008445764,0.0000026993641,0.035171293,0.00009977371,0.028279448,0.18241906],"study_design_scores_gemma":[0.64328086,0.008317336,0.02487554,0.00023453828,0.0018851752,0.000026181624,0.0004844099,0.010462333,0.14749765,0.0005207674,0.16124997,0.0011652566],"about_ca_topic_score_codex":0.0005900247,"about_ca_topic_score_gemma":0.00011300884,"teacher_disagreement_score":0.39004478,"about_ca_system_score_codex":0.00017773613,"about_ca_system_score_gemma":0.0003713597,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4323307162","doi":"10.1159/000529996","title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Bevacizumab; Medicine; Atezolizumab; Sorafenib; Internal medicine; Hepatocellular carcinoma; Liver function; Gastroenterology; Population; Post-hoc analysis; Oncology; Tolerability; Clinical endpoint; Surgery; Randomized controlled trial; Adverse effect; Cancer; Chemotherapy; Nivolumab","score_opus":0.09168397289620757,"score_gpt":0.3275482401496349,"score_spread":0.23586426725342735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323307162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961253,0.0013565028,0.000002603258,0.00007284853,0.000113633956,0.0019508848,0.00026553593,0.000035508732,0.00007720209],"genre_scores_gemma":[0.9990663,0.00009141218,0.000017592874,0.000019735673,0.000028345023,0.00020224764,0.000276749,0.000042923184,0.0002547141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971956,0.000208717,0.0006358304,0.0005623641,0.0009235664,0.00047394462],"domain_scores_gemma":[0.9982098,0.00014511628,0.0003329608,0.0008242902,0.00034772532,0.00014016012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002149375,0.0003577183,0.0011515128,0.000907575,0.00009801365,0.000015714582,0.00029466808,0.00011004326,0.00029324586],"category_scores_gemma":[0.00003696513,0.00023757173,0.0004547224,0.0048740627,0.00016322052,0.000110483634,0.00015650401,0.00020616803,0.0000066815037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013166373,0.0019444629,0.9751662,0.00012280348,0.0043391716,0.00020459363,0.00321587,0.00018826331,0.0009952849,0.0000049264695,0.000045512304,0.00060652214],"study_design_scores_gemma":[0.05404129,0.004155851,0.8965807,0.000103510196,0.011547751,8.058176e-7,0.0013241646,0.01710134,0.014826042,0.0000017120503,0.00003371357,0.00028315454],"about_ca_topic_score_codex":0.018030692,"about_ca_topic_score_gemma":0.0039034968,"teacher_disagreement_score":0.07858555,"about_ca_system_score_codex":0.00041306973,"about_ca_system_score_gemma":0.0004216397,"threshold_uncertainty_score":0.98850834},"labels":[],"label_agreement":null},{"id":"W4388621275","doi":"10.1159/000534303","title":"Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Oncology; Bevacizumab; Atezolizumab; Nivolumab; Adverse effect; Immunotherapy; Gastroenterology; Cancer; Chemotherapy","score_opus":0.05778974049913274,"score_gpt":0.2666817629775639,"score_spread":0.20889202247843117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388621275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97367615,0.023669565,0.0000031644665,0.0004791569,0.0003147325,0.0015670281,0.00017957744,0.00005428861,0.00005637171],"genre_scores_gemma":[0.9925082,0.00466307,0.00013465948,0.00005830297,0.0004465631,0.0005841372,0.00018601876,0.00007718821,0.0013418617],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756014,0.00010718466,0.0009773202,0.00047483764,0.00044406008,0.0004364384],"domain_scores_gemma":[0.99880254,0.0000885804,0.0003017554,0.00050456985,0.00017493735,0.00012759959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002624538,0.00042601177,0.00095052447,0.00048413532,0.00003922767,0.000010672509,0.000118085896,0.00025429745,0.0024056302],"category_scores_gemma":[0.000016723105,0.00030683985,0.00056441367,0.0010583127,0.00018592754,0.00010769527,0.000058225534,0.00019328846,0.000024686597],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009757154,0.0008970641,0.8268126,0.00028720364,0.00038328956,0.0010198617,0.0020276431,0.0000032037815,0.14946657,0.00000945096,0.00025922272,0.0090767],"study_design_scores_gemma":[0.017559018,0.0030747727,0.17805016,0.00069850084,0.00016359058,0.000020770454,0.00016836783,0.00083887804,0.79311705,0.000020027443,0.0059439014,0.00034498633],"about_ca_topic_score_codex":0.002333048,"about_ca_topic_score_gemma":0.00046221493,"teacher_disagreement_score":0.64876246,"about_ca_system_score_codex":0.00037254233,"about_ca_system_score_gemma":0.00045224646,"threshold_uncertainty_score":0.99993837},"labels":[],"label_agreement":null},{"id":"W4392015401","doi":"10.1159/000537966","title":"Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; BeiGene","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Carcinoma","score_opus":0.16634803674419976,"score_gpt":0.36027343846891813,"score_spread":0.19392540172471837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392015401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96056676,0.036067836,0.0000029572673,0.00062022713,0.00021580105,0.002141004,0.00014412699,0.000029949348,0.00021135136],"genre_scores_gemma":[0.9976474,0.0015047131,0.000020046295,0.000018844734,0.00006471422,0.00031410827,0.00012614255,0.00003373148,0.00027028593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763566,0.00025098227,0.0009259386,0.0004427444,0.0004131933,0.0003315063],"domain_scores_gemma":[0.99892217,0.00033555346,0.00016739528,0.00034054578,0.00007607088,0.00015825241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003555431,0.0002883528,0.00096321944,0.00040648817,0.000033590433,0.00001026556,0.0000714333,0.000114520655,0.00070106564],"category_scores_gemma":[0.0000423355,0.00022155169,0.00025231324,0.0007613647,0.000050031063,0.000081803046,0.00002207997,0.00016016113,0.000019412588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057406127,0.0030508924,0.9810784,0.0004892806,0.00049812085,0.0003973901,0.004711199,0.00026091936,0.00012223107,0.00006863594,0.000104057624,0.0034782533],"study_design_scores_gemma":[0.026860872,0.012091737,0.9356171,0.0005515221,0.00025359847,0.0000037507418,0.00046742908,0.021296732,0.0023326916,0.000038858903,0.00021537166,0.00027036012],"about_ca_topic_score_codex":0.0858881,"about_ca_topic_score_gemma":0.010245032,"teacher_disagreement_score":0.07564307,"about_ca_system_score_codex":0.0014353979,"about_ca_system_score_gemma":0.00095921825,"threshold_uncertainty_score":0.92019904},"labels":[],"label_agreement":null},{"id":"W4392151488","doi":"10.1159/000537947","title":"Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Eisai; Plexxikon; Seagen; Pfizer; NuCana; Incyte; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; EA Pharma Co., Ltd.; Merck KGaA; Baxalta; Sirtex Medical; Cancer Research UK; Boston Scientific Corporation; Halozyme; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Radiology; Clinical trial; Phases of clinical research","score_opus":0.043133913455944174,"score_gpt":0.28076085218210206,"score_spread":0.2376269387261579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392151488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439776,0.0010561448,0.000014604211,0.00017666469,0.000043673466,0.0040179,0.000065137385,0.000031583746,0.00019655305],"genre_scores_gemma":[0.9980798,0.00009945847,0.000038069673,0.000098990844,0.00005149013,0.0010222078,0.0002567022,0.00003629804,0.00031701592],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99824905,0.00045160815,0.00037819459,0.0003123634,0.00037550647,0.0002332448],"domain_scores_gemma":[0.99926233,0.00024990845,0.000107219596,0.00024350343,0.00009179506,0.000045251727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005065583,0.00021421412,0.0006172727,0.0003122234,0.000029703513,0.00003314916,0.00008262148,0.000057104502,0.00016596734],"category_scores_gemma":[0.000040608465,0.000112824004,0.000090808484,0.0008856495,0.00009459822,0.0001408228,0.000011286486,0.0001698434,0.00000366133],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46060428,0.0004215738,0.53518444,0.00012291771,0.000096194715,0.00037252792,0.0009811147,2.4510948e-7,0.0016524986,0.0000127731455,0.000008497802,0.0005429397],"study_design_scores_gemma":[0.84485424,0.0035567319,0.12080397,0.0009227816,0.0006296606,0.000007695547,0.00005620738,0.0032731628,0.02529629,0.0000042628726,0.00038739096,0.00020758374],"about_ca_topic_score_codex":0.0015962318,"about_ca_topic_score_gemma":0.00012701616,"teacher_disagreement_score":0.4143805,"about_ca_system_score_codex":0.00013150612,"about_ca_system_score_gemma":0.00027048666,"threshold_uncertainty_score":0.46008292},"labels":[],"label_agreement":null},{"id":"W4401410496","doi":"10.1159/000540290","title":"Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital","funders":"National Cancer Institute; University of California, San Francisco; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Memorial Sloan-Kettering Cancer Center","keywords":"Neratinib; Medicine; Sunitinib; Everolimus; Axitinib; Tyrosine-kinase inhibitor; Nivolumab; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Cancer; Immunotherapy; Clinical trial; Breast cancer","score_opus":0.007036782436839323,"score_gpt":0.2275670107357827,"score_spread":0.22053022829894336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401410496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675834,0.0019474182,0.000112838905,0.000096317504,0.00019813409,0.00072254264,0.000060286187,0.0000192751,0.00008486444],"genre_scores_gemma":[0.99757993,0.00006890468,0.0012403341,0.000069606525,0.00014738998,0.00016608267,0.00012985086,0.000080916914,0.0005169643],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981284,0.00008827449,0.00046485127,0.0005878172,0.0003769729,0.00035368587],"domain_scores_gemma":[0.99923074,0.000019980043,0.00018491532,0.00032997393,0.00015896338,0.000075407464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018742213,0.00033130645,0.00039969603,0.00018090462,0.000035726407,0.000037854625,0.00016514478,0.00017839028,0.00010778438],"category_scores_gemma":[0.000015830652,0.00021256784,0.000048020545,0.0005704858,0.00016850019,0.000031627074,0.000060988288,0.0002418068,0.000002067366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009629192,0.00032813422,0.9244326,0.0004787717,0.00016608572,0.000093255934,0.0013738481,0.0014670448,0.060242295,0.0000074853842,0.0004049185,0.0013763731],"study_design_scores_gemma":[0.010015172,0.0065756436,0.18056987,0.001801432,0.00008401485,0.000013064911,0.00029797718,0.0006178651,0.7967381,0.0000055425953,0.002514608,0.00076674594],"about_ca_topic_score_codex":0.0009985995,"about_ca_topic_score_gemma":0.002914813,"teacher_disagreement_score":0.74386275,"about_ca_system_score_codex":0.00017987416,"about_ca_system_score_gemma":0.0005852869,"threshold_uncertainty_score":0.8668265},"labels":[],"label_agreement":null},{"id":"W4404467870","doi":"10.1159/000542146","title":"Acknowledgement to Reviewers","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Acknowledgement; Medicine; Computer science; Computer security","score_opus":0.09618991736786028,"score_gpt":0.32425520200210406,"score_spread":0.22806528463424378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404467870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5175384,0.39149627,0.00035901726,0.014443204,0.0030900973,0.0021783784,0.000038086593,0.00044136462,0.07041514],"genre_scores_gemma":[0.9675451,0.00520889,0.0005675483,0.0015445709,0.0005876314,0.00028692983,0.000010993468,0.00002216364,0.024226181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99944955,0.000011026424,0.000087229324,0.00019281707,0.000121396166,0.00013796886],"domain_scores_gemma":[0.9996781,0.000011830706,0.000005621206,0.00013563973,0.0000453155,0.00012351142],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006313445,0.00008311232,0.00012870945,0.00006254866,0.000020360641,0.000020760193,0.00003229163,0.000026954833,0.004346195],"category_scores_gemma":[0.000008696672,0.000063781714,0.000094956165,0.00021014242,0.00000987777,0.000032206794,0.000023343639,0.000057363748,0.0031792037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045647226,0.0000633328,0.12976658,0.0009850139,0.00031284156,0.00055969664,0.0010993414,3.7081676e-7,0.0009084872,0.0004611167,0.3585561,0.5072415],"study_design_scores_gemma":[0.00015512791,0.000111464156,0.005086321,0.00063448824,0.00026978468,0.0000049853793,0.000011035755,0.00034682476,0.0028599822,0.00001136289,0.990427,0.000081616396],"about_ca_topic_score_codex":0.000054659464,"about_ca_topic_score_gemma":0.000019479194,"teacher_disagreement_score":0.6318709,"about_ca_system_score_codex":0.00014435776,"about_ca_system_score_gemma":0.00007531496,"threshold_uncertainty_score":0.9975969},"labels":[],"label_agreement":null},{"id":"W4414450104","doi":"10.1159/000548606","title":"Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Overall survival; Clinical endpoint; Progression-free survival; Endpoint Determination; Survival analysis","score_opus":0.1833565736483253,"score_gpt":0.33732170470501216,"score_spread":0.15396513105668685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414450104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98021054,0.015193303,0.00013280482,0.0012089455,0.0001465951,0.0024927738,0.00017371001,0.000010741738,0.00043060287],"genre_scores_gemma":[0.9962485,0.00058104395,0.00036556218,0.0004774421,0.00004151667,0.0014338857,0.000058808102,0.00001764022,0.0007756073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998201,0.00026181067,0.00055762846,0.00037908906,0.0002912149,0.00030922313],"domain_scores_gemma":[0.9988721,0.00039081927,0.00014492362,0.00045258054,0.00010442474,0.000035139517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070720527,0.00024293952,0.0012514925,0.0003194752,0.00003940968,0.000014880453,0.00019005021,0.0001082766,0.00040643394],"category_scores_gemma":[0.00003522163,0.00016330469,0.0012449652,0.0009200339,0.000050915998,0.00007534435,0.000026203514,0.00021356047,0.0000019923655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028525505,0.00074423215,0.92813456,0.00018313747,0.032153774,0.00009154916,0.0023813182,0.000055478373,0.0008670684,0.0004456342,0.0001115858,0.0063061677],"study_design_scores_gemma":[0.16890176,0.0015427645,0.6613477,0.00013245926,0.13269848,0.0000025325687,0.0005825933,0.010240332,0.01860321,0.0006842933,0.0045867246,0.00067715783],"about_ca_topic_score_codex":0.0064734123,"about_ca_topic_score_gemma":0.004506005,"teacher_disagreement_score":0.26678684,"about_ca_system_score_codex":0.00015258831,"about_ca_system_score_gemma":0.00024610022,"threshold_uncertainty_score":0.97859055},"labels":[],"label_agreement":null},{"id":"W4417466987","doi":"10.1159/000549955","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Ramucirumab; Chemoradiotherapy; Carcinoma","score_opus":0.09119294205123218,"score_gpt":0.3126555805677392,"score_spread":0.221462638516507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417466987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852231,0.007714768,0.000024175373,0.0014362118,0.000053567295,0.00481498,0.00056887633,0.00003245966,0.00013184012],"genre_scores_gemma":[0.9963387,0.0009833388,0.00012941695,0.00011455133,0.00008425508,0.0014520634,0.000090028276,0.00003200841,0.00077564013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817437,0.00010380222,0.00044377337,0.0006124702,0.00027320476,0.0003924069],"domain_scores_gemma":[0.99870425,0.00043079266,0.00015042975,0.0003841407,0.00016381053,0.00016660121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020302614,0.00032734274,0.00062778103,0.00008266926,0.000265777,0.00004446017,0.00009205862,0.00009028929,0.000048138154],"category_scores_gemma":[0.000058241,0.00019692382,0.000094794384,0.00027851027,0.00012838998,0.00008447171,0.000060122355,0.00009412164,0.0000014601868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019941153,0.0023701244,0.9506425,0.000114142604,0.0014752577,0.0001349787,0.00816974,0.0000024948013,0.00031704927,0.000013639538,0.00012812378,0.01669078],"study_design_scores_gemma":[0.14884956,0.033108037,0.7462116,0.00090303295,0.010308211,0.000012108499,0.003221436,0.020772537,0.030949192,0.00006416881,0.0050569214,0.0005432209],"about_ca_topic_score_codex":0.030320816,"about_ca_topic_score_gemma":0.0042252694,"teacher_disagreement_score":0.20443094,"about_ca_system_score_codex":0.00016055682,"about_ca_system_score_gemma":0.00024736772,"threshold_uncertainty_score":0.9761364},"labels":[],"label_agreement":null}]}